A COMPANY based in Dundee, Scotland which pioneers revolutionary, market-leading biotechnology has uplevelled its commitment to the US following a string of successes in a key market.
Cellexus International Ltd (Cellexus) has made significant investment in the US market, the biggest for its innovative bioreactors, by ploughing funds into the manufacture of bioreactor bags for its CellMaker system. Working with Vonco Products, LLC in Indiana has ensured that consumable stock is held in-country for the first time, extending the company’s reach and efficiency.
The move is seen as instrumental in maximising efficient response to a growing number of customer enquiries, particularly from the emerging bacteriophage market, and will act as a springboard towards future growth following the landmark sale of a system to a leading Houston medical centre earlier this year. It is also being examined by Indiana University for its potential in optimising the process for viral vector production.
From the company’s research, development and manufacturing base in Dundee, Cellexus provides its CellMaker range of the only single use, purely airlift bioreactor systems on the market to customers across the life sciences sector, including biotech laboratories and academic settings. The patented system is fully customisable to ensure bespoke solutions for customers thus offering a faster route to market than incumbent technologies.
Cellexus was acquired by its current management in 2017 and is headed by CEO Gavin Hands. He said: “This financial input allows us to hold consumable stock in the US for the first time, enabling us to further reduce our response times to a flourishing customer base.
“We have also redoubled our efforts to explore additional opportunities in the US by spending more time in country so that we can not only enhance our presence within the market but also grow and consolidate relationships there.”
To find out more, visit www.cellexus.com